CorMedix (NASDAQ:CRMD) Releases Quarterly Earnings Results

CorMedix (NASDAQ:CRMD) released its quarterly earnings data on Thursday. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.35 by $0.08, Zacks reports. CorMedix had a net margin of 45.25% and a return on equity of 49.12%. The firm had revenue of $127.43 million for the quarter, compared to the consensus estimate of $104.96 million. During the same period in the previous year, the company earned $0.30 earnings per share. The company’s quarterly revenue was up 226.1% on a year-over-year basis.

Here are the key takeaways from CorMedix’s conference call:

• CorMedix reported Q1 2026 net revenue of $127.4 million and adjusted EBITDA of $70 million, both reflecting strong execution and ahead of expectations. Management said the quarter benefited from durable DefenCath demand and the full-quarter contribution from the Melinta portfolio.
• The company raised full-year guidance, increasing net revenue to $325 million-$345 million and adjusted EBITDA to $115 million-$135 million. It also lifted DefenCath guidance to $175 million-$195 million, citing continued utilization strength.
• Management expects DefenCath revenue variability in the second half of 2026 as TDAPA reimbursement expires and the product moves to the post-TDAPA add-on phase. The company expects a higher net selling price in 2027 and said its near-term priority is to maintain or grow patient utilization.
• Preliminary top-line results from the ReSPECT phase III study showed REZZAYO met its primary endpoint and was non-inferior to standard antifungal therapy, with a favorable safety profile. CorMedix said the data support pursuing an sNDA submission in the second half of 2026 and a potential commercial launch in 2027.
• The Nutri-Guard TPN study is progressing slowly, with enrollment at only about one-third of the level needed for the interim analysis and completion now trending toward 2028. CorMedix plans to add sites and seek an FDA protocol amendment to broaden eligibility and speed enrollment.

CorMedix Trading Down 4.8%

CRMD opened at $7.55 on Friday. CorMedix has a twelve month low of $6.13 and a twelve month high of $17.43. The company has a 50-day simple moving average of $7.10 and a 200 day simple moving average of $8.66. The company has a quick ratio of 1.94, a current ratio of 2.11 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $592.24 million, a price-to-earnings ratio of 3.54 and a beta of 1.46.

CorMedix announced that its board has authorized a stock buyback program on Monday, February 2nd that permits the company to buyback $75.00 million in shares. This buyback authorization permits the company to buy up to 12.3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On CorMedix

Several institutional investors and hedge funds have recently bought and sold shares of CRMD. Deerfield Management Company L.P. bought a new stake in CorMedix during the third quarter worth about $38,656,000. Marshall Wace LLP lifted its holdings in shares of CorMedix by 34.6% in the third quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock worth $40,397,000 after acquiring an additional 893,518 shares during the last quarter. UBS Group AG lifted its holdings in shares of CorMedix by 295.3% in the third quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock worth $12,687,000 after acquiring an additional 814,964 shares during the last quarter. Jump Financial LLC bought a new position in shares of CorMedix in the third quarter worth about $9,003,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of CorMedix by 259.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 828,781 shares of the company’s stock worth $9,639,000 after acquiring an additional 597,971 shares during the last quarter. Institutional investors own 34.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CRMD. Leerink Partners boosted their target price on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. Royal Bank Of Canada reissued an “outperform” rating and issued a $14.00 target price (up from $13.00) on shares of CorMedix in a research report on Tuesday, April 28th. Zacks Research cut shares of CorMedix from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 10th. HC Wainwright reduced their target price on shares of CorMedix from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Finally, D. Boral Capital reissued a “buy” rating and issued a $14.00 target price on shares of CorMedix in a research report on Monday, April 27th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Key CorMedix News

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: CorMedix beat Q1 estimates, with DefenCath driving triple-digit revenue growth and supporting a higher full-year outlook. CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
• Positive Sentiment: The company raised FY2026 revenue guidance to $325 million-$345 million, above Wall Street expectations, signaling management confidence in continued demand and execution. CorMedix Q1 2026 Financial Results and Business Update
• Positive Sentiment: CorMedix announced upcoming investor conference participation, which could help keep attention on the name and provide more updates on growth strategy. CorMedix to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst commentary and earnings-call recaps are reinforcing the same message: strong quarterly performance, improving profitability, and continued momentum in the core product. Analysts Offer Insights on Healthcare Companies: Immatics and CorMedix
• Neutral Sentiment: Unusually heavy options activity suggests traders expect continued volatility around the earnings-driven move in CRMD.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.